Matrix metalloproteinases: fold and function of their catalytic domains.
暂无分享,去创建一个
[1] X. Puente,et al. Human and mouse proteases: a comparative genomic approach , 2003, Nature Reviews Genetics.
[2] C. López-Otín,et al. Emerging roles of proteases in tumour suppression , 2007, Nature Reviews Cancer.
[3] Roberto Mosca,et al. RAPIDO: a web server for the alignment of protein structures in the presence of conformational changes , 2008, Nucleic Acids Res..
[4] H. Nagase. Activation mechanisms of matrix metalloproteinases. , 1997, Biological chemistry.
[5] F. Gomis-Rüth. Catalytic Domain Architecture of Metzincin Metalloproteases* , 2009, The Journal of Biological Chemistry.
[6] Christopher M. Overall,et al. In search of partners: linking extracellular proteases to substrates , 2007, Nature Reviews Molecular Cell Biology.
[7] B. Matthews,et al. An interactive computer graphics study of thermolysin-catalyzed peptide cleavage and inhibition by N-carboxymethyl dipeptides. , 1984, Biochemistry.
[8] Brian W. Matthews,et al. Structural basis of the action of thermolysin and related zinc peptidases , 1988 .
[9] W. Stetler-Stevenson,et al. TIMP-2: an endogenous inhibitor of angiogenesis. , 2005, Trends in molecular medicine.
[10] G. Butler,et al. Mechanisms for pro matrix metalloproteinase activation , 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[11] Gomis-Rüth Fx,et al. Structure and Mechanism of Metallocarboxypeptidases , 2008, Critical reviews in biochemistry and molecular biology.
[12] J. Cha,et al. Metal and pH dependence of heptapeptide catalysis by human matrilysin. , 1996, Biochemistry.
[13] B. Fingleton,et al. Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.
[14] W. Bode,et al. Structure determination and analysis of human neutrophil collagenase complexed with a hydroxamate inhibitor. , 1995, Biochemistry.
[15] Per E M Siegbahn,et al. Catalytic mechanism of matrix metalloproteinases: two-layered ONIOM study. , 2002, Inorganic chemistry.
[16] G. Murphy. The ADAMs: signalling scissors in the tumour microenvironment , 2008, Nature Reviews Cancer.
[17] R. Fridman,et al. Processing, shedding, and endocytosis of membrane type 1‐matrix metalloproteinase (MT1‐MMP) , 2004, Journal of cellular physiology.
[18] Ekaterina Morgunova,et al. Structural insight into the complex formation of latent matrix metalloproteinase 2 with tissue inhibitor of metalloproteinase 2 , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[19] C. Overall,et al. The Canonical Methionine 392 of Matrix Metalloproteinase 2 (Gelatinase A) Is Not Required for Catalytic Efficiency or Structural Integrity , 2004, Journal of Biological Chemistry.
[20] C. Lapière. Tadpole collagenase, the single parent of such a large family. , 2005, Biochimie.
[21] V. Dive,et al. Synthetic active site-directed inhibitors of metzincins: achievement and perspectives. , 2008, Molecular aspects of medicine.
[22] K. Iwata,et al. Growth‐promoting activity of tissue inhibitor of metalloproteinases‐1 (TIMP‐1) for a wide range of cells A possible new growth factor in serum , 1992, FEBS letters.
[23] I. Bertini,et al. Snapshots of the reaction mechanism of matrix metalloproteinases. , 2006, Angewandte Chemie.
[24] How tadpoles lose their tails: path to discovery of the first matrix metalloproteinase. , 2004, Matrix biology : journal of the International Society for Matrix Biology.
[25] R. Huber,et al. Refined 1.8 A X-ray crystal structure of astacin, a zinc-endopeptidase from the crayfish Astacus astacus L. Structure determination, refinement, molecular structure and comparison with thermolysin. , 1994, Journal of molecular biology.
[26] B. Vallee,et al. Zinc coordination, function, and structure of zinc enzymes and other proteins. , 1990, Biochemistry.
[27] B. Matthews,et al. Binding of N-carboxymethyl dipeptide inhibitors to thermolysin determined by X-ray crystallography: a novel class of transition-state analogues for zinc peptidases. , 1984, Biochemistry.
[28] W. Bode,et al. 1.8-A crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate primed-side inhibitor with a distinct selectivity profile. , 1997, European journal of biochemistry.
[29] Pierre Ducrot,et al. Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors. , 2005, Bioorganic & medicinal chemistry letters.
[30] H. Nagase. Substrate Specificity of MMPs , 2001 .
[31] C. Janson,et al. Structure of the C-terminally truncated human ProMMP9, a gelatin-binding matrix metalloproteinase. , 2002, Acta crystallographica. Section D, Biological crystallography.
[32] C. Overall. Matrix MetaIIoproteinase Substrate Binding Domains, Modules and Exosites , 2001 .
[33] K. D. Hardman,et al. Roles of the propeptide and metal ions in the folding and stability of the catalytic domain of stromelysin (matrix metalloproteinase 3). , 1996, Biochemistry.
[34] B. Vallee,et al. Active-site zinc ligands and activated H2O of zinc enzymes. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[35] Carlos López-Otín,et al. Strategies for MMP inhibition in cancer: innovations for the post-trial era , 2002, Nature Reviews Cancer.
[36] H. Nagase,et al. Elucidating the Function of Non catalytic Domains of Collagenases and Aggrecanases , 2008, Connective tissue research.
[37] H. Birkedal‐Hansen,et al. Multiple modes of activation of latent human fibroblast collagenase: evidence for the role of a Cys73 active-site zinc complex in latency and a "cysteine switch" mechanism for activation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[38] W. Bode,et al. Expression, Purification, Characterization, and X-Ray Analysis of Selenomethionine 215 Variant of Leukocyte Collagenase , 1997, Journal of protein chemistry.
[39] M. Furue,et al. Tissue inhibitor of metalloproteinase 1 (TIMP-1) may be an autocrine growth factor in scleroderma fibroblasts. , 1997, The Journal of investigative dermatology.
[40] Seth M. Cohen,et al. New beginnings for matrix metalloproteinase inhibitors: identification of high-affinity zinc-binding groups. , 2004, Journal of the American Chemical Society.
[41] C. López-Otín,et al. Matrilysin-2, a new matrix metalloproteinase expressed in human tumors and showing the minimal domain organization required for secretion, latency, and activity. , 2000, Cancer research.
[42] K. Appelt,et al. Matrix Metalloproteinase Inhibitors for Cancer Therapy , 2000, Cancer Drug Discovery and Development.
[43] B. G. Rao,et al. Recent developments in the design of specific Matrix Metalloproteinase inhibitors aided by structural and computational studies. , 2005, Current pharmaceutical design.
[44] U. Baumann,et al. The conserved methionine residue of the metzincins: a site-directed mutagenesis study. , 2001, Journal of molecular biology.
[45] D. Edwards,et al. The ADAM metalloproteinases , 2008, Molecular Aspects of Medicine.
[46] Philippe Cuniasse,et al. Development of Selective Inhibitors and Substrate of Matrix Metalloproteinase-12* , 2006, Journal of Biological Chemistry.
[47] R. Visse,et al. This Review Is Part of a Thematic Series on Matrix Metalloproteinases, Which Includes the following Articles: Matrix Metalloproteinase Inhibition after Myocardial Infarction: a New Approach to Prevent Heart Failure? Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: the Good, the Ba , 2022 .
[48] M. Milla,et al. Key feature of the catalytic cycle of TNF-α converting enzyme involves communication between distal protein sites and the enzyme catalytic core , 2007, Proceedings of the National Academy of Sciences.
[49] R. Huber,et al. Structural implications for the role of the N terminus in the ‘superactivation’ of collagenases , 1994, FEBS letters.
[50] Z. Werb,et al. New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.
[51] F. Beau,et al. Phosphinic peptides as zinc metalloproteinase inhibitors , 2004, Cellular and Molecular Life Sciences CMLS.
[52] Sangsoo Kim,et al. The x-ray crystallographic study of covalently modified carboxypeptidase A by 2-benzyl-3,4-epoxybutanoic acid, a pseudomechanism-based inactivator , 1992 .
[53] A. Berger,et al. On the size of the active site in proteases. I. Papain. , 1967, Biochemical and biophysical research communications.
[54] H. Birkedal‐Hansen,et al. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[55] W. Bode,et al. Structural basis of matrix metalloproteinases and tissue inhibitors of metalloproteinases , 2003, Molecular biotechnology.
[56] U. Baumann,et al. Metzincin's canonical methionine is responsible for the structural integrity of the zinc-binding site , 2009, Biological chemistry.
[57] H. Birkedal‐Hansen,et al. Matrix metalloproteinases: a review. , 1993, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.
[58] R. Huber,et al. Handbook of metalloproteins , 2006 .
[59] S V Evans,et al. SETOR: hardware-lighted three-dimensional solid model representations of macromolecules. , 1993, Journal of molecular graphics.
[60] C. Lapière,et al. Collagenolytic activity in amphibian tissues: a tissue culture assay. , 1962, Proceedings of the National Academy of Sciences of the United States of America.
[61] G. Schneider,et al. Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. , 1999, Science.
[62] D. Hupe,et al. A Rationalization of the Acidic pH Dependence for Stromelysin-1 (Matrix Metalloproteinase-3) Catalysis and Inhibition* , 2000, The Journal of Biological Chemistry.
[63] H. Nagase,et al. Progress in matrix metalloproteinase research. , 2008, Molecular aspects of medicine.
[64] S. Meroueh,et al. Structural Basis for Potent Slow Binding Inhibition of Human Matrix Metalloproteinase-2 (MMP-2)* , 2003, Journal of Biological Chemistry.
[65] W. Bode,et al. Astacins, serralysins, snake venom and matrix metalloproteinases exhibit identical zinc‐binding environments (HEXXHXXGXXH and Met‐turn) and topologies and should be grouped into a common family, the ‘metzincins’ , 1993, FEBS letters.
[66] H. Fraser,et al. Expression of tissue inhibitor of metalloproteinases-1 in the primate ovary during induced luteal regression. , 1996, The Journal of endocrinology.
[67] P. Reinemer,et al. The metzincins — Topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a super family of zinc‐peptidases , 1995, Protein science : a publication of the Protein Society.
[68] D. Auld,et al. Catalytic mechanisms for metallopeptidases , 2004 .
[69] K. Maskos. Crystal structures of MMPs in complex with physiological and pharmacological inhibitors. , 2005, Biochimie.
[70] M. Milla,et al. The TACE zymogen , 2007, Cell Biochemistry and Biophysics.
[71] K Ulrich Wendt,et al. Structural basis for the highly selective inhibition of MMP-13. , 2005, Chemistry & biology.
[72] A. H. Drummond,et al. Hydroxamic Acid Matrix Metalloproteinase Inhibitors , 2001 .
[73] R. Huber,et al. Activation of snake venom metalloproteinases by a cysteine switch‐like mechanism , 1993, FEBS letters.
[74] Constance E. Brinckerhoff,et al. Matrix metalloproteinases: a tail of a frog that became a prince , 2002, Nature Reviews Molecular Cell Biology.
[75] F. Gomis-Rüth,et al. Structural aspects of the metzincin clan of metalloendopeptidases , 2003, Molecular biotechnology.
[76] T. Blundell. Metalloproteinase super–families and drug design , 1994, Nature Structural Biology.
[77] Dong H. Kim. Chemistry-based design of inhibitors for carboxypeptidase A. , 2004, Current topics in medicinal chemistry.
[78] J. Springer,et al. Stromelysin‐1: Three‐dimensional structure of the inhibited catalytic domain and of the C‐truncated proenzyme , 1995, Protein science : a publication of the Protein Society.
[79] Jerry March,et al. Advanced Organic Chemistry: Reactions, Mechanisms, and Structure , 1977 .
[80] U. Baumann,et al. Molecular Analysis of Ulilysin, the Structural Prototype of a New Family of Metzincin Metalloproteases* , 2006, Journal of Biological Chemistry.
[81] M. Overgaard,et al. Regulation of Human ADAM 12 Protease by the Prodomain , 1999, The Journal of Biological Chemistry.
[82] Neil D. Rawlings,et al. Handbook of proteolytic enzymes , 1998 .
[83] W. Bode,et al. Structural Studies on MMPs andTIMPs Wolfram Bode and Klaus Maskos , 2001 .
[84] W. Bode,et al. X-ray Structure of Human proMMP-1 , 2005, Journal of Biological Chemistry.
[85] Gonzalo R. Ordóñez,et al. The Degradome database: mammalian proteases and diseases of proteolysis , 2008, Nucleic Acids Res..
[86] A. Papatsoris,et al. Matrix metalloproteinase inhibitors as anticancer agents. , 2008, The international journal of biochemistry & cell biology.
[87] A. Hassell,et al. Crystal structures of recombinant 19-kDa human fibroblast collagenase complexed to itself. , 1995, Biochemistry.
[88] C. Overall,et al. Towards third generation matrix metalloproteinase inhibitors for cancer therapy , 2006, British Journal of Cancer.
[89] R. Montanari,et al. Extra binding region induced by non-zinc chelating inhibitors into the S1' subsite of matrix metalloproteinase 8 (MMP-8). , 2009, Journal of medicinal chemistry.